Obstetrics and gynecology · 2005
Malignant mixed mullerian tumor of the uterus in a patient taking raloxifene.
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Goldman Noah A, de Los Angeles Maria M, Jones Joan G, Goldberg Gary L
Аннотация
BACKGROUND: Uterine malignant mixed mesodermal tumor is a rare variant of uterine cancer. Data suggest that tamoxifen is involved in the pathogenesis. We report a case of a women in whom a malignant mixed mesodermal tumor was diagnosed while she was taking raloxifene, which is also a selective estrogen receptor modulator.
CASE: A malignant mixed mesodermal tumor was diagnosed in a 64-year-old woman with a bicornuate uterus while she was taking raloxifene for osteoporosis prevention. Diagnosis had been delayed secondary to sampling of the other uterine horn.
CONCLUSION: There may be an association between raloxifene and the development of malignant mixed mesodermal tumor. Special attention should be paid when attempting to sample the endometrium in patients with mullerian abnormalities.
CASE: A malignant mixed mesodermal tumor was diagnosed in a 64-year-old woman with a bicornuate uterus while she was taking raloxifene for osteoporosis prevention. Diagnosis had been delayed secondary to sampling of the other uterine horn.
CONCLUSION: There may be an association between raloxifene and the development of malignant mixed mesodermal tumor. Special attention should be paid when attempting to sample the endometrium in patients with mullerian abnormalities.
Предметные рубрики MeSH
Biopsy, NeedleChemotherapy, AdjuvantCombined Modality TherapyFemaleFollow-Up StudiesHumansHysterectomyImmunohistochemistryMiddle AgedMixed Tumor, MullerianNeoplasm StagingOsteoporosis, PostmenopausalOvariectomyRadiotherapy, AdjuvantRaloxifene HydrochlorideSelective Estrogen Receptor ModulatorsTreatment OutcomeUterine Neoplasms